Anti-Human CD3 x CD20 (Epcoritamab) (C3260-1.0mg)

Epcoritamab is a CD20xCD3 Bispecific T cell Engager (BiTE) antibody developed as a cancer immunotherapeutic drug 1 . Simultaneous targeting of CD20 B cell on lymphomas and CD3 on T cells, leads to T cell activation, the release of perforin and granzymes, and ultimately the depletion of malignant B cells through lysis and cell death 1 . This approach is potent in treating B-cell malignancies like non-Hodgkin lymphoma. The distribution of Anti-Human CD3 x CD20 includes blood and lymphatic tissues, enabling effective engagement with T and B-cells, enhancing its therapeutic efficacy2-4. Epcoritamab (GEN3013) is a bispecific antibody that targets CD3 on T-cells and CD20 on B- cells, inducing potent T-cell-mediated cytotoxicity against CD20-expressing B-cells. Administered subcutaneously, Epcoritamab has demonstrated significant efficacy in clinical trials for relapsed or refractory B-cell lymphomas. In laboratory settings, Epcoritamab is utilized to study bispecific antibody mechanisms and develop therapeutic strategies for B-cell malignancies5-7.